Siddig Ibrahim Abdelwahab, Manal Mohamed Elhassan Taha, Hassan Ahmad Ahmad Alfaifi, Amal Hamdan Alzahrani, Ieman A Aljahdali, Omar Oraibi, Sohaila Ali, Bassem Oraibi, Abdullah Farasani, Ahmed Ali Jerah, Yasir Osman Hassan Babiker, Anas A Ahmed, Gassem Gohal, Osama Albasheer
{"title":"Trends in Research on Gantenerumab for Alzheimer's Disease: A Bibliometric and Thematic Analysis.","authors":"Siddig Ibrahim Abdelwahab, Manal Mohamed Elhassan Taha, Hassan Ahmad Ahmad Alfaifi, Amal Hamdan Alzahrani, Ieman A Aljahdali, Omar Oraibi, Sohaila Ali, Bassem Oraibi, Abdullah Farasani, Ahmed Ali Jerah, Yasir Osman Hassan Babiker, Anas A Ahmed, Gassem Gohal, Osama Albasheer","doi":"10.2174/0118715273349645250324040257","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gantenerumab (GR), a promising therapeutic agent for Alzheimer's disease (AD), has been the subject of extensive research. In this study, we aimed to provide a comprehensive analysis of the literature on GR.</p><p><strong>Methods: </strong>A systematic search was conducted using the PubMed, Scopus, and Web of Science databases. VOSviewer and Bibliometrix were utilized to analyze bibliographic data.</p><p><strong>Results: </strong>The analysis of the literature on GR revealed distinct publication trends. Reviews accounted for 52% of the records, followed by research articles (31%). The United States contributed the highest proportion of publications (26%). The Journal of Prevention of Alzheimer's Disease was the most prolific source (21 articles). The annual number of publications increased steadily from 2009 to 2024. Major international collaborations were observed among the United States, the United Kingdom, Switzerland, France, and Sweden. Research activity consistently centered on key themes, such as amyloid imaging, biomarkers, clinical trials, and β-amyloid. Thematic mapping identified specialized subfields, core research areas, and dynamic shifts in topics, offering a comprehensive overview of the GR research landscape.</p><p><strong>Conclusion: </strong>GR-related literature showed sustained thematic focus, growing international collaboration, and a steady rise in publication volume within the field of AD. These findings highlight the continued need for clinical and biomarker-focused investigations to advance therapeutic development in AD.</p>","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715273349645250324040257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gantenerumab (GR), a promising therapeutic agent for Alzheimer's disease (AD), has been the subject of extensive research. In this study, we aimed to provide a comprehensive analysis of the literature on GR.
Methods: A systematic search was conducted using the PubMed, Scopus, and Web of Science databases. VOSviewer and Bibliometrix were utilized to analyze bibliographic data.
Results: The analysis of the literature on GR revealed distinct publication trends. Reviews accounted for 52% of the records, followed by research articles (31%). The United States contributed the highest proportion of publications (26%). The Journal of Prevention of Alzheimer's Disease was the most prolific source (21 articles). The annual number of publications increased steadily from 2009 to 2024. Major international collaborations were observed among the United States, the United Kingdom, Switzerland, France, and Sweden. Research activity consistently centered on key themes, such as amyloid imaging, biomarkers, clinical trials, and β-amyloid. Thematic mapping identified specialized subfields, core research areas, and dynamic shifts in topics, offering a comprehensive overview of the GR research landscape.
Conclusion: GR-related literature showed sustained thematic focus, growing international collaboration, and a steady rise in publication volume within the field of AD. These findings highlight the continued need for clinical and biomarker-focused investigations to advance therapeutic development in AD.
背景：Gantenerumab （GR）是一种治疗阿尔茨海默病（AD）的有前景的药物，一直是广泛研究的主题。在这项研究中，我们的目的是提供一个关于gr的文献的综合分析。方法：使用PubMed， Scopus和Web of Science数据库进行系统检索。利用VOSviewer和Bibliometrix对书目数据进行分析。结果：对GR的文献分析显示出明显的出版趋势。评论占记录的52%，其次是研究文章（31%）。美国贡献了最高比例的出版物（26%）。阿尔茨海默病预防杂志是最多产的来源（21篇文章）。从2009年到2024年，每年的出版物数量稳步增长。美国、英国、瑞士、法国和瑞典进行了重要的国际合作。研究活动始终以关键主题为中心，如淀粉样蛋白成像、生物标志物、临床试验和β-淀粉样蛋白。专题地图确定了专门的子领域、核心研究领域和主题的动态变化，提供了GR研究前景的全面概述。结论：在AD领域内，gr相关文献呈现出持续的专题关注、日益增强的国际合作和稳步上升的出版量。这些发现强调了继续需要临床和以生物标志物为重点的研究来推进阿尔茨海默病的治疗发展。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
